drugset / Trial / NCT04348136
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
NaSingle-groupOpen-labelTreatment
Summary
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2030-03-31
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PABINAFUSP ALFA | Protein / enzyme biologic | 2 mg/kg | Intravenous |